US Mativ secures first order for Miru's smart window technology
Mativ (NYSE: MATV), global leader in specialty materials, has reached a significant milestone in their partnership with Miru Smart Technologies ('Miru'), a pioneer in smart window innovation. Through its advanced polymer film solutions brand, Argotec, Mativ has secured their first purchase order of materials used in Miru's dynamic electrochromic window technology from a major glass manufacturer. This achievement marks a major step forward in preparing the supply chain for large-scale production and global adoption of electrochromic glass by leading automotive OEMs, and aligns with Mativ's ongoing commitments around safety, sustainability, and innovation.
Miru collaborates with major global glass companies and key vendors in the supply chain to develop cutting-edge dynamic electrochromic windows ('eWindows') enabled by Argotec's specialty thermoplastic polyurethane (TPU) interlayer film. eWindows dynamically tint on demand, enhancing energy efficiency, comfort, and the passenger or user experience in automotive and architectural applications.
Mativ, through its Argotec brand, secured its first purchase order for specialty TPU film used in Miru Smart Technologies' dynamic electrochromic windows. This marks a key step towards large-scale production and adoption in automotive applications. The partnership underscores innovation and supply chain readiness, with both firms set to showcase the tech at GPD 2025 in Finland.
This agreement secures a significant volume of Argotec specialty TPU interlayer film, a critical component in Miru's eWindow stack. The joint technology delivers optical clarity, durability, and manufacturability for next-generation eWindow systems.
The purchase order follows extensive co-development and materials testing between Mativ and Miru, signifying a key step forward in their strategic collaboration. A recent highlight in the partnership was the successful fabrication of one of the world's largest electrochromic sunroof devices - a compound-curved prototype measuring 1.5 m x 1.6 m - demonstrating scalability for next-generation vehicle design.
'This order reflects our confidence in the market demand for Miru's exciting eWindow technology and our shared commitment to customer-driven innovation platforms,' said Ryan Elwart, Group President of Mativ . 'Argotec's advanced films are engineered for the performance needs of smart glazing, and we are proud to support Miru in scaling electrochromic glass for the future of mobility.'
'This announcement marks a major step forward in our supply chain readiness,' said Curtis Berlinguette, Founder and CEO of Miru . 'Our partnership with Mativ ensures we have access to proven, scalable interlayer materials that meet the optical and mechanical performance standards of our eWindow system. We are excited to deepen this collaboration as we scale toward full production.'
Argotec and Miru will showcase their joint solution at Glass Performance Days (GPD) 2025 in Tampere, Finland (June 10 - 12). Attendees are invited to visit the booth (F9) to see the eWindow technology in action. The companies will also be hosting a networking mixer during GPD, bringing together innovators and industry leaders to explore the future of smart glass. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (RM)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Wire
a day ago
- The Wire
Noah Holdings and ARK Wealth Outline Strategic Wealth Allocation Framework for Navigating Market Volatility at Financial Forums in Hong Kong
HONG KONG, June 6, 2025 /PRNewswire/ — Noah Holdings Limited ('Noah' or the 'Company') (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors, and its internationally focused subsidiary, ARK Wealth Management, delivered key strategic … Continue reading "Noah Holdings and ARK Wealth Outline Strategic Wealth Allocation Framework for Navigating Market Volatility at Financial Forums in Hong Kong"
Economic Times
2 days ago
- Economic Times
Stablecoin bigwig Circle soars in debut on the New York Stock Exchange
The US-based issuer of one of the most popular cryptocurrencies made its debut on the New York Stock Exchange on Thursday and quickly saw its value soar amid heavy interest from crypto enthusiasts and investors. Circle Internet Group issues USDC, a stablecoin that can be traded at a 1-to-1 ratio for US dollars, and EURC, which can similarly be traded for euros. Stablecoins are a fast-growing corner of the cryptocurrency industry that offer a buffer against volatility because they are pegged to real-world assets, like US dollars or gold. That makes them a much more reliable means of conducting commercial transactions than other forms of crypto. Interest in Circle's initial public offering is high. The company's underwriters priced the offering at $31 per share Wednesday, up from an expected range of $27 to $28. The number of shares being sold was raised to 34 million from 32 million. Circle is listed on the NYSE under the symbol "CRCL." The stock price soared above $96 at one point Thursday afternoon and landed at $83.23 by closing. Circle's initial public offering is one of the biggest public listings for a crypto-related company since the exchange Coinbase went public in 2021. The dominant player in the stablecoin field is El Salvador-based Tether, which has the stablecoin known as USDT that currently has about $150 billion in circulation. USDC is the second most popular stablecoin market cap, with about $60 billion in circulation. Circle said in a regulatory filing that USDC has been used for more than "$25 trillion in onchain transactions" since its launch in 2018. Revenue-wise the company has seen tremendous growth, going from just $15 million in 2020 to $1.7 billion in 2024. Stablecoin issuers make profits by collecting the interest on the assets they hold in reserve to back their stablecoins. Circle said USDC is backed by "cash, short-dated US Treasuries and overnight US Treasury repurchase agreements with leading global banks." Circle's IPO comes amid a push by the Trump administration and the crypto industry to pass legislation that would regulate how stablecoin issuers operate in the US A Senate bill advanced last month with bipartisan support. There is also growing competition in the stablecoin field. A crypto enterprise partly owned by the Trump family just launched its own stablecoin, USD1. Circle said its long track record and values - the company says its mission statement is "to raise global economic prosperity through the frictionless exchange of value" - will help it stand apart in the field.
Time of India
2 days ago
- Time of India
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets. 'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange filing. Keytruda, a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars market. This partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive activity. Under the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain exceptions. The deal is expected to accelerate development timelines and expand the global market reach of the biosimilar. Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing expertise. With this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment. 'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Dr. Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE. Also read: Positive Breakout: These 5 stocks cross above their 200 DMAs ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
